SCHEMBL5044035

SCHEMBL5044035

CC1(C)CCC(C)(C)c2c(NCc3ccc(F)cc3)cc(C(=O)C=Cc3ccc(C(=O)O)c(O)c3)cc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 4/20 0.37
RARB P10826 4/20 0.37
CTSL P07711 1/20 0.37
CXCL12 P48061 1/20 0.37
PPARA Q07869 1/20 0.37
STING1 Q86WV6 1/20 0.37
APP P05067 1/20 0.36
RARG P13631 3/20 0.36
CISD1 Q9NZ45 1/20 0.36
HDAC4 P56524 2/20 0.35
MEF2D Q14814 2/20 0.35
RXRA P19793 2/20 0.35
P4HB P07237 2/20 0.35
CYP26A1 O43174 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
ATM Q13315 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5044033 1.00 RARA (0.37) RARARARBCTSLCXCL12PPARA
SCHEMBL5048389 0.92 HNF4A (0.37) RARARARBCXCL12APPRARG
SCHEMBL5048390 0.92 HNF4A (0.37) RARARARBCXCL12APPRARG
SCHEMBL5047252 0.90 MAOB (0.42) APPMEN1ALDH1A1LMNAMAPT
SCHEMBL5047247 0.90 MAOB (0.42) APPMEN1ALDH1A1LMNAMAPT
SCHEMBL5048417 0.89 RARA (0.46) RARARARBRARGHDAC4MEF2D
SCHEMBL5048411 0.89 RARA (0.46) RARARARBRARGHDAC4MEF2D
SCHEMBL5047070 0.84 APP (0.38) RARARARBCXCL12APPRARG
SCHEMBL5047079 0.84 RARA (0.38) RARARARBCTSLCXCL12RARG
SCHEMBL5047081 0.84 RARA (0.38) RARARARBCTSLCXCL12RARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US claimed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US claimed
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US disclosed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG RARA 1/4885RARB 2/4885CTSL 2798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.